OTPE 19 2001 y

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

tertify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: nt Commissioner for Patents, Washington, D.C. 20231, on October 15, 2001.

Nora Derant

10/24

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Gary J. BRIDGER, et al.

Serial No .:

09/535,314

Filing Date:

24 March 2000

For:

CHEMOKINE RECEPTOR BINDING

HETEROCYCLIC COMPOUNDS

Examiner:

Venkataraman Balasubramanian (Bala)

Group Art Unit: 1624

AMENDMENT UNDER 37 C.F.R. § 1.111

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

This is in response to an Office Action herein mailed 13 August 2001, time for response to which was set to expire 13 September 2001. A petition for an extension of time of one (1) month until 13 October 2001 is attached hereto, along with the required fee. Restriction was required among nine groups.

Applicants hereby elect to prosecute the invention of group IX drawn to claims wherein the X variants comprise a fused ring system where a 5- or 6-membered ring is fused to a 5- to 7-membered ring. Applicants were further asked to designate species within this group specifying ring size for each ring and the nature of the heteroatoms. Applicants hereby elect to prosecute the species wherein both members of the fused ring system (ring A and ring B) are 6-membered

rings and the heteroatom is nitrogen. The species wherein a single nitrogen heteroatom occurs is hereby elected. The species specifically elected is compound 8907, the preparation of which is described on page 112 of the specification in Example 61. The structure of this compound appears in Figure 1 on page 247.

The claims herein have been amended to conform with this election. As it is not specified, applicants assume that the restriction between inventions is satisfied by electing group IX and that the remaining elections constitute elections of species. The claims have been amended accordingly. It may be that some compounds in canceled claims 97 and 99-101 should be reinstated in accordance with this election. Applicants will review the specification for an accurate list of compounds in due course.

It is believed that the new restriction requirement has been complied with, and examination on the merits is requested.

Enclosed is the following Exhibit A: Marked-up Version of Amendments to the Specification and Claims.